...
首页> 外文期刊>American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons >Renal transplantation across HLA and ABO antibody barriers: integrating paired donation into desensitization protocols.
【24h】

Renal transplantation across HLA and ABO antibody barriers: integrating paired donation into desensitization protocols.

机译:跨越HLA和ABO抗体屏障的肾脏移植:将配对捐赠整合到脱敏方案中。

获取原文
获取原文并翻译 | 示例
           

摘要

The field of desensitization and incompatible transplantation has made great gains over the past decade. There are now several options and effective therapies for many patients who face antibody barriers. Kidney paired donation (KPD) and desensitization have traditionally been considered competing strategies and patients have been offered one or the other without regard for the probability of a successful outcome. It is now possible to predict which donor/recipient phenotypes will benefit from each of these modalities. KPD should be favored among patients with immunologic phenotypes that are likely to match without prolonged waiting times. However, as many as 50% of patients with incompatible donors will fail to find a match in a KPD pool and many of these patients could be desensitized to their donor. Positive crossmatch and ABO incompatible transplantation has been accomplished in selective cases without the need for heavy immunosuppression or B-cell ablative therapy. Patients who are both difficult-to-match due to broad sensitization and hard-to-desensitize because of strong donor reactivity can often be successfully transplanted through a combination of desensitization and KPD. Using these various modalities it is estimated that most patients with incompatible live donors can undergo successful renal transplantation.
机译:在过去的十年中,脱敏和不相容移植领域取得了巨大进展。对于面对抗体障碍的许多患者,现在有几种选择和有效的疗法。肾脏配对捐赠(KPD)和脱敏传统上一直被认为是竞争策略,并且为患者提供了一种或另一种选择,而不考虑成功结果的可能性。现在可以预测哪种供体/受体表型将从这些方式中受益。免疫表型在不延长等待时间就可能匹配的免疫表型患者中应优先使用KPD。但是,多达50%的供体不兼容的患者将无法在KPD库中找到匹配的患者,并且其中许多患者可能会对其供体不敏感。在选择性病例中,无需大量免疫抑制或B细胞消融治疗,即可完成阳性交叉匹配和ABO不相容移植。由于广泛的致敏性而难以匹配且由于强烈的供体反应性而难以脱敏的患者通常可以通过脱敏和KPD的组合成功移植。使用这些各种方式,估计大多数具有不相容活体供体的患者都可以成功进行肾移植。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号